Bayer AG said it's “determined to enforce intellectual property” after losing a bid to demand royalties from Abbott Laboratories over U.S. sales of the arthritis drug Humira.

Europe's largest drug and chemical maker, which sued Abbott in 2008 for violating its intellectual-property rights, conceded in a court filing yesterday that Humira doesn't infringe its patent under an interpretation by a judge in the case. Bayer's lawsuit can be revived if an appeals court overturns the judge's definition of the phrase “human monoclonal antibodies.”

Read the full Bloomberg story, “Bayer is “Determined” to Defend Property Rights After Losing Bid on Humira